“The results suggest that THC:CBD may serve as a valuable addition in the spectrum of symptomatic therapy in ALS.”
A new study published in BMC Neurology provides the first real world data (outside a clinical trial) on the dosing of THC:CBD in amyotrophic lateral sclerosis (ALS).
ALS is a severe, progressive and incurable neurodegenerative disorder.
The study found that“THC:CBD (Sativex) may serve as a valuable addition in the spectrum of symptomatic therapy in ALS.”
Patients reported high satisfaction with the treatment.
Sativex (GW Pharmaceuticals) increasingly being used off-label for spasticity treatment of persons with ALS.